NCT00738764已完成1 期
A Phase 1, Multicenter, Open-Label, Dose Escalation Trial of PDL192 in Subjects With Advanced Solid Tumors
Abbott2 个研究点 分布在 1 个国家目标入组 30 人开始时间: 2008年7月1日最近更新:
适应症
干预措施
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 30
- 试验地点
- 2
- 主要终点
- Maximum tolerated dose
研究概览
简要总结
This is a phase 1, multicenter, open-label, dose escalation trial of PDL192 in subjects with advanced solid tumors.
详细描述
The primary study objective is to determine the maximum tolerated dose of PDL192 in subjects with advanced solid tumors.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Eligible subjects will be considered for inclusion in this study if they meet all of the following criteria:
- •Male or female, 18 years of age or older.
- •Subjects with documented advanced solid tumors.
- •Subjects who have previously failed all standard therapies or subjects who have a tumor where no standard therapy exists.
- •A negative serum pregnancy test (women of childbearing potential only) at screening. Male or female subjects of reproductive potential must be willing to use adequate contraception during the duration of the study and for a minimum of 3 months after the end of treatment.
- •Ability to understand the purpose and risks of the study and provide signed and dated informed consent and authorization to use protected health information (in accordance with national and local subject privacy regulations).
排除标准
- •Subjects will be ineligible for this study if they meet any one of the following criteria:
- •Symptomatic and progressive central nervous system (CNS) metastases or leptomeningeal metastases
- •Diagnosis of glioblastoma
- •Eastern Cooperative Oncology Group (ECOG) performance status >= 2
- •Abnormal hematologic values defined as:
- •Hemoglobin level < 9 g/dL
- •Absolute neutrophil count (ANC) < 1500/mm3
- •Platelet count < 100,000/mm3
- •Abnormal kidney, liver, or pancreatic function defined as:
- •Serum creatinine > 1.5 x upper limit of normal value (ULN)
- •Aspartate transaminase or alanine transaminase levels of > = 2.5 x ULN
- •Bilirubin > ULN
- •Amylase > 1.5 x ULN
- •Lipase > 1.5 x ULN
- •Known chronic viral hepatitis
- •History of cirrhotic liver disease
- •History of pancreatitis (patients with history of gall stone pancreatitis who are status post-cholecystectomy will be eligible)
- •Acute cholecystitis within 6 months prior to the first dose of study drug
- •Treatment with any investigational drug, antineoplastic agent, or antibodies within 21 days prior to the first dose of study drug (6 weeks for vaccines or nitrosureas)
- •Proteinuria >1 g/24 hours (only subjects with > = 2+ with dipstick test will undergo 24 hour urine collection)
- •Ongoing >= Grade 2 toxicities resulting from prior therapies
- •Received continuous systemic steroids at doses greater than 10 mg/day of prednisone or its equivalent within 30 days prior to the first dose of study drug (intermittent dexamethasone given for prophylaxis or treatment of emesis is permitted)
- •Received any immunosuppressive agent (except steroids) within 21 days prior to the first dose of study drug
- •Known hypersensitivity to any component of the PDL192 formulation
- •Uncontrolled medical problems such as diabetes mellitus, pancreatitis, coronary artery disease, hypertension, unstable angina, arrhythmias, pulmonary disease, or symptomatic heart failure
- •Female subjects who are pregnant or breastfeeding
研究组 & 干预措施
Cohort 6
Experimental
PDL192 Dose Level 6
干预措施: PDL192 (Biological)
Cohort 5
Experimental
PDL192 Dose Level 5
干预措施: PDL192 (Biological)
Cohort 4
Experimental
PDL192 Dose Level 4
干预措施: PDL192 (Biological)
Cohort 3
Experimental
PDL192 Dose Level 3
干预措施: PDL192 (Biological)
Cohort 2
Experimental
PDL192 Dose Level 2
干预措施: PDL192 (Biological)
Cohort 1
Experimental
PDL192 Dose Level 1
干预措施: PDL192 (Biological)
结局指标
主要结局
Maximum tolerated dose
时间窗: after four weeks of dosing
次要结局
- The incidence and frequency of dose-limiting toxicities; The frequency, severity, and relationship of adverse events and serious adverse events;Incidence of abnormal findings in physical examinations and clinical laboratory values(during estimated average 4 month treatment period and 90 day follow up)
- Pharmacokinetic profile of PDL192 including maximum serum drug concentration, area under the concentration-time curve from time zero to infinity, systemic clearance, volume of distribution, and elimination half-life(during estimated average 4 month treatment period and 90 day follow up)
- Incidence of PDL192-specific antidrug antibodies(during estimated average 4 month treatment period and 90 day follow up)
- Objective response rate (Complete Response + Partial Response) and Disease control rate (Complete Response + Partial Response + Stable Disease)(during estimated average 4 month treatment period)
研究者
研究点 (2)
Loading locations...
相似试验
暂停
1 期
IMM2902, a HER2/SIRPα Bispecific MAb-Trap Antibody-receptor Fusion Protein, in Patients with HER2-expressing Advanced Solid TumorsAdvanced Breast CancerAdvanced Solid TumorAdvanced Gastric CancerNCT05076591ImmuneOnco Biopharmaceuticals (Shanghai) Inc.135
招募中
1 期
SB17170 Phase 1 Clinical Trial in Solid TumorsSolid TumorNCT05522868SPARK Biopharma50
已完成
1 期
Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy, Phase 1 Study of CMG901Advanced Solid TumorGastric Cancer(Including Gastroesophageal Junction Adenocarcinoma)Pancreatic CancerNCT04805307Keymed Biosciences Co.Ltd176
已完成
1 期
Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Intravenous TKM-080301 in Subjects With Advanced Hepatocellular CarcinomaHepatomaLiver Cancer, AdultLiver Cell Carcinoma, AdultHepatocellular CarcinomaNCT02191878Arbutus Biopharma Corporation43
终止
1 期
Evaluate the Safety of BEL-X-HG in Advanced Cancer PatientsAdvanced Solid TumorsNCT03256331Belx Bio-Pharmaceutical (Taiwan) Corporation23